KORU Medical (KRMD) Q2 2026: International Revenue Jumps 59% as Platform Expansion Accelerates

2026-08-05 | By EarningsIQ Research

KORU Medical delivered a pivotal quarter, returning to positive net income while international core revenue surged 59% year over year. The company’s disciplined expansion into pre-filled syringe markets and connected health capabilities is driving a multi-year platform transformation, though regional launch complexity is moderating near-term growth. With new device launches, digital integration, and regulatory catalysts on the horizon, KORU is positioning itself to capture a larger share of the evolving subcutaneous drug delivery market.

Summary

• International Ramp Outpaces Expectations: High-volume distributor sales and pre-filled syringe conversions fueled sharp OUS growth.
• Platform Evolution Gains Traction: Connected health acquisition and pipeline progress advance KORU’s shift beyond mechanical devices.
• Near-Term Growth Moderates: Regional launch delays temper 2026 outlook, but long-term market opportunity remains robust.

Business Overview

KORU Medical Systems designs, manufactures, and sells subcutaneous infusion systems for chronic and specialty drug delivery at home and in alternate care settings. Its core business centers on the Freedom Infusion System, serving roughly 60,000 recurring immunoglobulin (IG) patients, with revenue generated from pumps, consumable supplies, and pharma services. Major segments include Domestic Core (U.S. IG and non-IG therapies), International Core (Europe and other geographies, often via distributor partners), and Pharma Services & Technology (PST, clinical trials and drug development support).

Performance Analysis

KORU posted record quarterly revenue, with international core revenue jumping 59% year over year, driven by distributor demand and pre-filled syringe adoption in Europe. Domestic core sales grew 12%, reflecting continued market share gains and patient retention in the U.S. core IG market. However, PST revenue fell 35% due to clinical trial order timing, highlighting the segment’s inherent variability.

Gross margin improved to 65.1%, up 160 basis points YoY, as manufacturing efficiencies, higher average selling prices, and a favorable customer mix offset cost pressures. The company reached positive net income for the first time since 2019, underpinned by operating leverage and spending discipline. Cash usage was minimal, and KORU ended the quarter with $8.3 million in cash, supported by positive cash flow from operations and an undrawn $10 million credit facility.

• International Conversion Drives Upside: Distributor-led adoption of pre-filled syringes in Europe accelerated pump and consumable sales.
• Margin Expansion Outpaces Guidance: Supplier contract renegotiation and cost control lifted gross margin above the 2026 target range.
• PST Segment Lumpy, But Strategic: Clinical trial order timing caused volatility, but long-term pharma partnerships remain a pipeline growth engine.

While near-term international ramp is moderating due to regional launch complexity, management remains confident in the long-term growth trajectory as foundational commercial and regulatory groundwork is laid in new markets.

Executive Commentary

Strategic Positioning

1. International Market Expansion

KORU’s international business is in a high-growth phase, with pre-filled syringe conversions and distributor-led patient starts fueling rapid adoption. However, the move from tender-driven to competitive, relationship-based markets in Europe requires methodical channel development, which is slowing the pace of ramp in some regions. Management is prioritizing permanent market leadership through disciplined groundwork in distribution and reimbursement, even at the expense of short-term growth.

2. Platform Diversification and Digital Health

The acquisition of a connected monitoring technology asset marks a strategic pivot toward integrating digital capabilities into KORU’s core mechanical systems. This will enable real-time data capture for both patients and pharma partners, supporting adherence tracking and clinical trial data integrity. The move is a multi-year build, but positions KORU as a future leader in connected drug delivery, expanding its value proposition beyond devices.

3. Regulatory and Pipeline Leverage

Regulatory progress continues with the Freedom360 pump and new non-IG indications, including deferoxamine and oncology biologics. The withdrawal of the Fezgo application in the U.S. reflects a focus on higher-return molecules, while international oncology opportunities remain active. Ongoing clinical trials in secondary immunodeficiency (SID) could unlock new reimbursed patient populations, significantly expanding KORU’s addressable market.

4. Domestic Market Outperformance

The U.S. core IG business continues to outperform underlying market growth, with robust new patient starts and high retention. Ristigo, a non-IG therapy, validates the platform’s ability to diversify indications and further penetrate the domestic market.

5. Pharma Services Pipeline

While PST revenue is volatile, the segment embeds KORU in multi-year pharma development cycles, providing long-term growth optionality as more therapies adopt subcutaneous delivery.

Key Considerations

This quarter underscores KORU’s strategic shift from a device manufacturer to a connected platform player, with investments in international market access, digital health, and regulatory expansion shaping the growth profile.

Key Considerations:

• International Launch Complexity: Regional market dynamics and distribution setup are slowing the pre-filled syringe ramp, deferring some revenue into 2027.
• Connected Health Differentiation: The technology asset acquisition will enable future real-world evidence generation and adherence support, a differentiator in pharma partnerships.
• Margin Resilience: Supplier contract extensions and efficiency gains are de-risking gross margin, supporting profitability even as growth investments continue.
• Regulatory Pipeline as Growth Catalyst: New drug and device submissions could expand the addressable market and diversify revenue beyond IG therapies.
• Pharma Services Volatility: PST revenue remains lumpy, but the segment’s strategic value lies in embedding KORU within emerging drug pipelines.

Risks

Execution risk remains high in international expansion, with timing of market conversions and distributor readiness introducing revenue variability. Regulatory hurdles, especially in bringing new drugs and devices on label, could delay pipeline realization. Competitive pressure from electronic pumps in Europe and evolving payer dynamics may impact pricing and adoption. The multi-year digital integration plan requires sustained investment and execution discipline.

Forward Outlook

For Q3 and Q4 2026, KORU guided to:

• Moderate international core growth as regional launch complexity extends ramp timelines
• Continued domestic outperformance and stable PST contribution

For full-year 2026, management narrowed revenue guidance to:

• $47.5 million to $48.5 million (timing-related, with some revenue deferred into 2027)
• Raised gross margin guidance to 62% to 64%
• Year-end cash balance expected above $7.5 million
• Positive adjusted EBITDA for the full year

Management highlighted:

• International revenue recognition in certain markets will shift more meaningfully into 2027
• Gross margin upside is supported by supplier contract renegotiation and ongoing cost improvements

Takeaways

KORU’s Q2 marks a strategic inflection, with international momentum, digital health investments, and regulatory catalysts positioning the company for multi-year growth.

• International Expansion Is a Double-Edged Sword: While OUS growth is robust, regional launch pacing introduces near-term unpredictability but sets up a larger long-term opportunity.
• Platform Transformation Underway: The move into connected health and next-gen devices signals a shift from niche device manufacturer to data-enabled drug delivery leader.
• Watch for Pipeline and Regulatory Milestones: New drug labels, device approvals, and SID market entry will be critical for sustaining 20%+ growth ambitions.

Conclusion

KORU Medical’s Q2 2026 results reflect a company in transition, balancing near-term launch execution with long-term platform expansion. Margin improvements and positive net income validate the business model, while new strategic levers—especially in digital and international—position KORU for durable growth as subcutaneous drug delivery adoption accelerates globally.

Industry Read-Through

The surge in pre-filled syringe adoption and the migration of chronic therapies to home and alternate care settings signal a broader market shift in drug delivery. KORU’s experience highlights the importance of regional launch discipline, distributor partnerships, and regulatory readiness for medtech firms expanding internationally. The integration of connected health features into legacy device platforms is emerging as a necessity for differentiation, patient engagement, and pharma collaboration. Companies reliant on clinical trial-driven PST revenue should expect ongoing volatility, but strategic embedding in pharma pipelines can drive long-term optionality. Margin resilience through supplier negotiations and cost control is increasingly vital as competitive intensity and payer scrutiny rise across the sector.

KRMD Healthcare Medical Devices Digital Health Infusion Therapy International Expansion Connected Devices Margin